119 related articles for article (PubMed ID: 7795140)
1. Economic issues in European self-sufficiency.
Szucs TD
Blood Coagul Fibrinolysis; 1994 Dec; 5 Suppl 4():S51-5. PubMed ID: 7795140
[TBL] [Abstract][Full Text] [Related]
2. Is haemophilia prophylaxis achievable in the context of self-sufficiency?
Nilsson IM
Blood Coagul Fibrinolysis; 1994 Dec; 5 Suppl 4():S71-5. PubMed ID: 7795143
[TBL] [Abstract][Full Text] [Related]
3. Should clinical freedom be constrained in the name of self-sufficiency?
Schimpf K
Blood Coagul Fibrinolysis; 1994 Dec; 5 Suppl 4():S47-9. PubMed ID: 7795139
[TBL] [Abstract][Full Text] [Related]
4. Utilization of care in haemophilia: a resource-based method for cost analysis from the Haemophilia Utilization Group Study (HUGS).
Globe DR; Curtis RG; Koerper MA;
Haemophilia; 2004 Mar; 10 Suppl 1():63-70. PubMed ID: 14987251
[TBL] [Abstract][Full Text] [Related]
5. Prophylactic use of factor VIII: an economic evaluation.
Bohn RL; Avorn J; Glynn RJ; Choodnovskiy I; Haschemeyer R; Aledort LM
Thromb Haemost; 1998 May; 79(5):932-7. PubMed ID: 9609224
[TBL] [Abstract][Full Text] [Related]
6. Cost effectiveness of haemophilia treatment: a cross-national assessment.
Lippert B; Berger K; Berntorp E; Giangrande P; van den Berg M; Schramm W; Siebert U;
Blood Coagul Fibrinolysis; 2005 Oct; 16(7):477-85. PubMed ID: 16175006
[TBL] [Abstract][Full Text] [Related]
7. [Prophylactic factor substitution in severe haemophilia A. Economic assessment in adult patients].
Berger K; Schopohl D; Eheberg D; Oldenburg J; Tiede A; Schramm W
Hamostaseologie; 2014; 34(4):291-300. PubMed ID: 25370177
[TBL] [Abstract][Full Text] [Related]
8. Some aspects on the management of hemophilia.
Aledort LM
Thromb Haemost; 1995 Jul; 74(1):440-3. PubMed ID: 8578502
[No Abstract] [Full Text] [Related]
9. How will immune tolerance protocols affect self-sufficiency goals?
Brackmann HH
Blood Coagul Fibrinolysis; 1994 Dec; 5 Suppl 4():S77-9. PubMed ID: 7795144
[TBL] [Abstract][Full Text] [Related]
10. Can the supply and demand for plasma-derived products ever be reconciled?
Kyburg LC
Blood Coagul Fibrinolysis; 1994 Dec; 5 Suppl 4():S19-21. PubMed ID: 7795133
[TBL] [Abstract][Full Text] [Related]
11. Secondary prophylaxis treatment versus on-demand treatment for patients with severe haemophilia A: comparisons of cost and outcomes in Taiwan.
Liou WS; Tu TC; Cheng SN; Chou TY; Lee CF; Lin TK; Chung MI; Cham TM
Haemophilia; 2011 Jan; 17(1):45-54. PubMed ID: 20722742
[TBL] [Abstract][Full Text] [Related]
12. The cost of severe haemophilia in Europe: the CHESS study.
O'Hara J; Hughes D; Camp C; Burke T; Carroll L; Diego DG
Orphanet J Rare Dis; 2017 May; 12(1):106. PubMed ID: 28569181
[TBL] [Abstract][Full Text] [Related]
13. Cost-utility analysis of Canadian tailored prophylaxis, primary prophylaxis and on-demand therapy in young children with severe haemophilia A.
Risebrough N; Oh P; Blanchette V; Curtin J; Hitzler J; Feldman BM
Haemophilia; 2008 Jul; 14(4):743-52. PubMed ID: 18422610
[TBL] [Abstract][Full Text] [Related]
14. Clinical outcomes and resource utilization associated with haemophilia care in Europe.
Schramm W; Royal S; Kroner B; Berntorp E; Giangrande P; Ludlam C; Gringeri A; Berger K; Szucs T;
Haemophilia; 2002 Jan; 8(1):33-43. PubMed ID: 11886463
[TBL] [Abstract][Full Text] [Related]
15. Will recent innovations in therapy save perceived deficiencies in self-sufficiency policies.
Limentani SA
Blood Coagul Fibrinolysis; 1994 Dec; 5 Suppl 4():S81-4. PubMed ID: 7795145
[TBL] [Abstract][Full Text] [Related]
16. Social/economic costs and quality of life in patients with haemophilia in Europe.
Cavazza M; Kodra Y; Armeni P; De Santis M; López-Bastida J; Linertová R; Oliva-Moreno J; Serrano-Aguilar P; Posada-de-la-Paz M; Taruscio D; Schieppati A; Iskrov G; Gulácsi L; von der Schulenburg JM; Kanavos P; Chevreul K; Persson U; Fattore G;
Eur J Health Econ; 2016 Apr; 17 Suppl 1():53-65. PubMed ID: 27048374
[TBL] [Abstract][Full Text] [Related]
17. Hemophilia home treatment. Economic analysis and implications for health policy.
Ross-Degnan D; Soumerai SB; Avorn J; Bohn RL; Bright R; Aledort LM
Int J Technol Assess Health Care; 1995; 11(2):327-44. PubMed ID: 7790175
[TBL] [Abstract][Full Text] [Related]
18. Resource utilisation in haemophiliacs treated in Europe: results from the European Study on Socioeconomic Aspects of Haemophilia Care. The European Socioeconomic Study Group.
Szucs TD; Offner A; Kroner B; Giangrande P; Berntorp E; Schramm W
Haemophilia; 1998 Jul; 4(4):498-501. PubMed ID: 9873781
[TBL] [Abstract][Full Text] [Related]
19. The economics of inpatient on-demand treatment for haemophilia with high-responding inhibitors: a US retrospective data analysis.
Pokras SM; Petrilla AA; Weatherall J; Lee WC
Haemophilia; 2012 Mar; 18(2):284-90. PubMed ID: 21812862
[TBL] [Abstract][Full Text] [Related]
20. Episodic versus prophylactic infusions for hemophilia A: a cost-effectiveness analysis.
Smith PS; Teutsch SM; Shaffer PA; Rolka H; Evatt B
J Pediatr; 1996 Sep; 129(3):424-31. PubMed ID: 8804333
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
